TACTI-002: A Phase II Study of Eftilagimod Alpha (Soluble LAG-3) & Pembrolizumab in 2nd line PD-1/PD-L1 Refractory Metastatic NSCLC

被引：0
|
作者：
Forster, M. [1 ]
Krebs, M. [2 ,3 ]
Majem, M. [4 ]
Peguero, J.
Clay, T. [5 ]
Felip, E. [6 ]
Iams, W. [7 ]
Roxburgh, P. [8 ,9 ]
Doger, B. [10 ]
Bajaj, P. [11 ]
Kefas, J. [12 ]
Scott, J. A. [13 ]
Joaquin, A. Barba [4 ]
Mueller, C. [14 ]
Triebel, F. [15 ]
机构：
[1] Univ Coll London Hosp NHS Fdn, Canc Inst, UCL, London, England
[2] Univ Manchester, Div Canc Sci, Manchester, England
[3] Christie NHS Fdn Trust, Manchester, England
[4] Hosp Santa Creu & Sant Pau, Barcelona, Spain
[5] Hosp St John God Subiaco, Perth, Australia
[6] Vall Hebron Univ Hosp, Barcelona, Spain
[7] Vanderbilt Ingram Canc Ctr, Div Hematol Oncol, Nashville, TN USA
[8] Univ Glasgow, Inst Canc Sci, Wolfson Wohl Canc Res Ctr, Glasgow, Scotland
[9] Beatson West Scotland Canc Ctr, Glasgow, Scotland
[10] Fdn Jimenez Diaz, Madrid, Spain
[11] Tasman Oncol, Southport, Australia
[12] Univ Coll London Hosp NHS Trust, London, England
[13] Christie NHS Fdn Trust, Manchester, England
[14] Immutep GmbH, Berlin, Germany
[15] Immutep SAS, Orsay, France
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
LAG-3; NSCLC; PD-1/PD-L1; refractory;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP08.01-10
引用
收藏
页码：S395 / S395
页数：1
相关论文
共 50 条
  • [41] Systemic levels of the soluble co-inhibitory immune checkpoints, CTLA-4, LAG-3, PD-1/PD-L1 and TIM-3 are markedly increased in basal cell carcinoma
    Malinga, Nonkululeko Z.
    Siwele, Shalete C.
    Steel, Helen C.
    Kwofie, Luyanda L., I
    Meyer, Pieter W. A.
    Smit, Teresa
    Anderson, Ronald
    Rapoport, Bernardo L.
    Kgokolo, Mahlatse C. M.
    TRANSLATIONAL ONCOLOGY, 2022, 19
  • [42] Implications of TCGA Network Data on 2nd Generation Immunotherapy Concepts Based on PD-L1 and PD-1 Target Structures
    Peters, I.
    Tezval, H.
    Kramer, M. W.
    Wolters, M.
    Gruenwald, V.
    Kuczyk, M. A.
    Serth, J.
    AKTUELLE UROLOGIE, 2015, 46 (06) : 481 - 485
  • [43] LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes
    He, Yayi
    Yu, Hui
    Rozeboom, Leslie
    Rivard, Christopher J.
    Ellison, Kim
    Dziadziuszko, Rafal
    Suda, Kenichi
    Ren, Shengxiang
    Wu, Chunyan
    Hou, Likun
    Zhou, Caicun
    Hirsch, Fred R.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (05) : 814 - 823
  • [44] Combined inhibition of PD-1/PD-L1, Lag-3, and Tim-3 axes augments antitumor immunity in gastric cancer–T cell coculture models
    Kosaku Mimura
    Ley-Fang Kua
    Jin-Fen Xiao
    Bernadette Reyna Asuncion
    Yuko Nakayama
    Nicholas Syn
    Zul Fazreen
    Richie Soong
    Koji Kono
    Wei-Peng Yong
    Gastric Cancer, 2021, 24 : 611 - 623
  • [45] Systemic levels of the soluble co-inhibitory immune checkpoints, CTLA-4, LAG-3, PD-1/PD-L1, and TIM-3 are markedly increased in basal cell carcinoma
    Rapoport, Bernardo Leon
    Malinga, Nonkululeko
    Siwele, Shalete
    Steel, Helen C.
    Kwofie, Luyanda Li
    Meyer, Pieter
    Smit, Teresa
    Anderson, Ronald
    Kgokolo, Mahlatse
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [46] PD-L1 Expression in Primary Tumour vs Metastatic Samples in The Phase 3 MYSTiC Study in First-Line Metastatic (m) NSCLC
    Wehler, T.
    Reinmuth, N.
    Boothman, A. -M
    Cho, B. C.
    Lee, K. H.
    Luft, A.
    Ahn, M. -J.
    Scott, M.
    Whiteley, J.
    Walker, J.
    Karwe, V.
    Mukhopadhyay, P.
    Thiyagarajah, P.
    Scheuring, U.
    Rizvi, N.
    de Wit, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 120 - 120
  • [47] Phase II study of enlonstobart (SG001), a novel PD-1 inhibitor in patients with PD-L1 positive recurrent/metastatic cervical cancer
    Li, Guiling
    Li, Xiaofan
    Yin, Rutie
    Feng, Mei
    Zuo, Jing
    Wei, Shuqing
    Kang, Shan
    Sun, Hongmei
    Li, Xiumin
    Wang, Yili
    Zhang, Yunyan
    Sun, Li
    Lin, Daren
    Ruan, Xiaohong
    Zhu, Zhitu
    Jiang, Kui
    Liup, Hu
    Wang, Wei
    Hao, Deshun
    Chen, Ying
    Xiang, Silong
    Niu, Miao
    Wu, Lingying
    GYNECOLOGIC ONCOLOGY, 2024, 191 : 165 - 171
  • [48] A phase II study of docetaxel (D), ramucirumab (R), and pembrolizumab (P) for pts with metastatic or recurrent non-small cell lung cancer (NSCLC) who progressed on platinum-doublet and PD-1/PD-L1 blockade
    El Osta, B.
    Carlisle, J.
    Steuer, C.
    Larijani, F. A.
    Dhodapkar, M.
    Rupji, M.
    Chen, Z.
    Liu, Y.
    Owonikoko, T. K.
    Ramalingam, S. S.
    Leal, T. A.
    ANNALS OF ONCOLOGY, 2024, 35 : S849 - S849
  • [49] An Indirect Comparison of Pembrolizumab Monotherapy Versus Ipilimumab plus Nivolumab for First-Line Metastatic NSCLC with PD-L1 TPS≥1%
    Halmos, B.
    Burke, T.
    Kalyvas, C.
    Insinga, R.
    Vandormael, K.
    Frederickson, A.
    Piperdi, B.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S23 - S24
  • [50] Combined inhibition of PD-1/PD-L1, Lag-3, and Tim-3 axes augments antitumor immunity in gastric cancer-T cell coculture models
    Mimura, Kosaku
    Kua, Ley-Fang
    Xiao, Jin-Fen
    Asuncion, Bernadette Reyna
    Nakayama, Yuko
    Syn, Nicholas
    Fazreen, Zul
    Soong, Richie
    Kono, Koji
    Yong, Wei-Peng
    GASTRIC CANCER, 2021, 24 (03) : 611 - 623
12345